In last trading session, Relay Therapeutics Inc (NASDAQ:RLAY) saw 1.12 million shares changing hands with its beta currently measuring 1.61. Company’s recent per share price level of $4.16 trading at $0.24 or 6.12% at ring of the bell on the day assigns it a market valuation of $696.31M. That closing price of RLAY’s stock is at a discount of -166.11% from its 52-week high price of $11.07 and is indicating a premium of 15.87% from its 52-week low price of $3.50.

For Relay Therapeutics Inc (RLAY), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.09. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.55 in the current quarter.

Relay Therapeutics Inc (NASDAQ:RLAY) trade information

Upright in the green during last session for gaining 6.12%, in the last five days RLAY remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $4.16 price level, adding 0.72% to its value on the day. Relay Therapeutics Inc’s shares saw a change of 0.97% in year-to-date performance and have moved 11.23% in past 5-day. Relay Therapeutics Inc (NASDAQ:RLAY) showed a performance of -6.73% in past 30-days.

Wall Street analysts have assigned a consensus price target of 18 to the stock, which implies a rise of 76.89% to its current value. Analysts have been projecting 16 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -284.62% in reaching the projected high whereas dropping to the targeted low would mean a loss of -284.62% for stock’s current value.

Relay Therapeutics Inc (RLAY) estimates and forecasts

This year revenue growth is estimated to fall -40.98% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.08M for the same. And 7 analysts are in estimates of company making revenue of 42.86k in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 9.43% while estimates for its earnings growth in next 5 years are of 1.60%.

Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders

SB INVESTMENT ADVISERS (UK) LTD is the top institutional holder at RLAY for having 27.9 million shares of worth $181.94 million. And as of 2024-06-30, it was holding 21.0093 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 11.7 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8125 of outstanding shares, having a total worth of $76.32 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 4.89 shares of worth $20.34 million or 2.92% of the total outstanding shares. The later fund manager was in possession of 3.87 shares on Sep 30, 2024 , making its stake of worth around $16.09 million in the company or a holder of 2.31% of company’s stock.